Thursday, April 11, 2019 3:41:45 PM
3 things could be happening here:
1. Somebody knows something isn't going well and they are slowly unloading their shares.
2. Somebody knows something good is going to happen, and they are slowly dropping to get in at a lower price.
3. We can simply speculate and wait for earnings.
1. Somebody knows something isn't going well and they are slowly unloading their shares.
2. Somebody knows something good is going to happen, and they are slowly dropping to get in at a lower price.
3. We can simply speculate and wait for earnings.
Recent VSTM News
- Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers • Business Wire • 04/10/2026 11:00:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/09/2026 08:14:51 PM
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/02/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 09:20:14 PM
- Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 • Business Wire • 03/17/2026 10:03:00 PM
- Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers • Business Wire • 03/17/2026 08:44:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 09:15:33 PM
- Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates • Business Wire • 03/04/2026 09:01:00 PM
- Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 • Business Wire • 02/18/2026 12:30:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/18/2026 02:43:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 09:10:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2026 12:30:33 PM
- Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers • Business Wire • 02/04/2026 12:30:00 PM
- $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors • PR Newswire (US) • 01/30/2026 03:19:00 PM
- $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors • PR Newswire (Canada) • 01/30/2026 03:19:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 09:58:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 09:57:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/14/2026 10:15:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/14/2026 10:13:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/14/2026 10:12:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/14/2026 10:11:29 PM
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/12/2026 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 09:16:07 PM

